Europe Biodefense Market Forecast to 2027 - By Size, Share, Growth by End User and Forecast| Business Market Insights

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Biodefense Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Biodefense Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Presence of Favourable Government Initiatives
5.1.2 Increasing Threat of Biological and Nuclear Weapons

5.2 Market Opportunities

5.2.1 Low R&D Funding by Government in Developing and Underdeveloped Economies

5.3 Future Trends

5.3.1 Predictive Analytics to Reshape Biodefense Market

5.4 Impact of Drivers and Restraints

6. Europe Biodefense Market Regional Analysis

6.1 Europe Biodefense Market Overview

6.2 Europe Biodefense Market Revenue 2017-2027 (US$ Million)

6.3 Europe Biodefense Market Forecast Analysis

7. Europe Biodefense Market Analysis – by Product

7.1 Anthrax

7.1.1 Overview
7.1.2 Anthrax: Europe Biodefense Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Small pox

7.2.1 Overview
7.2.2 Small pox: Europe Biodefense Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Botulism

7.3.1 Overview
7.3.2 Botulism: Europe Biodefense Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Radiation/Nuclear

7.4.1 Overview
7.4.2 Radiation/Nuclear: Europe Biodefense Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Biodefense Market – Europe Analysis

8.1 Europe

8.1.1 Europe Biodefense Market Breakdown, by Key Country, 2020 and 2027 (%)
8.1.1.1 Europe Biodefense Market – Revenue and Forecast Analysis – by Country
8.1.1.1 UK: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.1.1 UK: Europe Biodefense Market Breakdown, by Product

8.1.1.2 Germany: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.2.1 Germany: Europe Biodefense Market Breakdown, by Product

8.1.1.3 France: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.3.1 France: Europe Biodefense Market Breakdown, by Product

8.1.1.4 Russia: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.4.1 Russia: Europe Biodefense Market Breakdown, by Product

8.1.1.5 Italy: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.5.1 Italy: Europe Biodefense Market Breakdown, by Product

8.1.1.6 Rest of Europe: Europe Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

8.1.1.6.1 Rest of Europe: Europe Biodefense Market Breakdown, by Product

9. Competitive Landscape

9.1 Heat Map Analysis

9.2 Company Positioning and Concentration

10. Europe Biodefense Market Industry Landscape

10.1 Overview

10.2 Mergers and Acquisitions

10.3 Agreements, Collaborations, and Joint Ventures

10.4 New Product Launches

10.5 Expansions and Other Strategic Developments

11. Company Profiles

11.1 Bavarian Nordic

11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments

11.2 Alnylam Pharmaceuticals, Inc.

11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments

11.3 SIGA Technologies

11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments

11.4 Emergent BioSolutions Inc.

11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments

11.5 Cleveland Bio Labs

11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

11.6 Dynavax Technologies

11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments

11.7 Elusys Therapeutics, Inc.

11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments

11.8 Soligenix

11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments

11.9 Altimmune

11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments

11.10 Pluristem Therapeutics

11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

12. Appendix

12.1 About Business Market Insights